farglitazar
Small moleculeexperimental
Farglitazar is a peroxisome proliferator-activated receptor agonist which was formerly under development by GlaxoSmithKline, but has never been marketed. It progressed to phase II clinical trials for the treatment of hepatic fibrosis, but failed to show efficacy. After reaching phase III for type 2 diabetes, further development was discontinued. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2005 (NCT00244751)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
PPARG agonist
1000-fold less potent at PPARA. Last updated November 2009, discontinued?
Chemistry & pharmacology
Loading structure…
SMILES
Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1- Mol. weight
- 546.62 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFarglitazar ↗
- ChEMBLCHEMBL107367 ↗
Also known as
- farglitazar
- farglitazar
- farglitazar
- gi2570
- gi 2570
- gi-2570
- gi262570
- gi262570
- gi262570
- gi 262570
- gi-262570
- gi-262570
- gi-262570
- gi-262570x
- gi-262570x
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00244751 | Phase 2 | Nov 1, 2005 | GlaxoSmithKline |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2005 |
1 organizations
Page 1 / 1